GLP-1 Drugs and Dual Agonists Show Major Benefits for Obesity-Related Heart Failure with Preserved Ejection Fraction | Research

The takeaway

Landmark trials (STEP-HFpEF, SUMMIT) show that GLP-1 receptor agonists and dual GIP/GLP-1 agonists significantly improve symptoms, reduce heart failure worsening, and promote weight loss in obese patients with HFpEF regardless of diabetes status.

Benefits regardless of diabetes status
The STEP-HFpEF trials showed that semaglutide improved heart failure symptoms and reduced worsening events in obese HFpEF patients whether or not they had diabetes — expanding the potential treatment population well beyond the traditional diabetic indication.

What the researchers found

The STEP-HFpEF, STEP-HFpEF DM, and SUMMIT trials demonstrated that incretin-based therapies — both GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists — significantly improved heart failure symptoms, reduced heart failure worsening events, and induced weight loss in obese HFpEF patients, regardless of whether they also had diabetes.

The review also notes that SGLT2 inhibitors and non-steroidal MRAs show prognostic benefits in HFpEF with post hoc analyses suggesting enhanced efficacy in higher-BMI subgroups. The authors propose that combining incretin-based therapies with SGLT2 inhibitors and non-steroidal MRAs may be the optimal evidence-based strategy for this patient population.

Why it matters

Obesity-related HFpEF is one of the fastest-growing cardiovascular conditions worldwide, with limited treatment options until recently. The demonstration that incretin-based peptide therapies can meaningfully improve both heart failure outcomes and body weight in these patients represents a paradigm shift — treating both the cardiac disease and its metabolic driver simultaneously with a single drug class.

How the study worked

This is a comprehensive narrative review synthesizing evidence from landmark randomized controlled trials (STEP-HFpEF, STEP-HFpEF DM, SUMMIT), post hoc subgroup analyses, and mechanistic studies on pharmacotherapies for obesity-related HFpEF. The review evaluates GLP-1 RAs, dual GIP/GLP-1 agonists, SGLT2 inhibitors, MRAs, ARNIs, bariatric surgery, and novel agents.

What this study cannot tell us

Long-term cardiovascular mortality benefits and safety profiles of incretin-based therapies in HFpEF require further validation — the current trials primarily assessed symptoms and functional outcomes over relatively short follow-up periods. There are no randomized trials comparing bariatric surgery outcomes specifically for HFpEF. Optimal BMI thresholds for treatment, weight loss targets, and combination strategies remain undefined. Cost and access barriers to these newer medications are not fully addressed.

How to read the evidence

This is a comprehensive review synthesizing evidence from multiple landmark randomized controlled trials (STEP-HFpEF, STEP-HFpEF DM, SUMMIT). The underlying trial evidence is high quality, though the review itself is narrative rather than systematic, and some combination therapy recommendations are based on post hoc analyses rather than dedicated trials.

When this study was published

Published in 2025, this is a very current review incorporating the latest landmark trial data including STEP-HFpEF and SUMMIT results. The treatment landscape it describes reflects the current state of the art.

The bigger picture

This review captures a transformative moment in cardiology where obesity is being recognized not just as a risk factor for heart failure but as a treatable driver of the disease. The convergence of successful obesity pharmacotherapy with heart failure treatment represents a new paradigm in cardiometabolic medicine. The proposed triple combination strategy (incretin + SGLT2 inhibitor + MRA) could become a standard of care for the growing population of obese HFpEF patients.

Questions still open

Will longer-term trials confirm that GLP-1 drugs reduce cardiovascular mortality — not just symptoms — in obese HFpEF patients?
What is the optimal combination and sequencing of incretin therapies, SGLT2 inhibitors, and MRAs for maximal benefit in obesity-related HFpEF?
Is there a BMI threshold below which incretin-based therapy no longer provides meaningful HFpEF benefit?

Common questions

What is HFpEF and why is obesity making it more common?

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure where the heart pumps normally but becomes stiff and can't fill with blood properly. Obesity drives HFpEF through multiple mechanisms: excess body fat increases inflammation, raises blood volume, promotes insulin resistance, and puts mechanical stress on the heart. As obesity rates rise globally, HFpEF has become one of the fastest-growing cardiovascular conditions.

How do GLP-1 drugs help with heart failure, not just weight loss?

GLP-1 receptor agonists appear to benefit HFpEF through multiple mechanisms: they promote significant weight loss (reducing the mechanical and metabolic burden on the heart), reduce systemic inflammation, improve blood vessel function, and may have direct cardiac protective effects. Landmark trials like STEP-HFpEF showed improvements in heart failure symptoms, exercise capacity, and quality of life beyond what would be expected from weight loss alone.

Read the original research

Advances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review.

Current heart failure reports, 22(1), 33

View on PubMed ↗Publisher’s paper ↗

Citation

Wu, Ying; Song, Meiyan; Chen, Xiaomin; Chen, Wen; Wu, Meifang; Lin, Liming. (2025). Advances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review.. Current heart failure reports, 22(1), 33. https://doi.org/10.1007/s11897-025-00722-z